The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.
Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY tri
The European Commission has moved swiftly to grant full approval to Roche's Actemra/RoActemra as a treatment for severe COVID-19, clearing the drug within 24 hours of a recommendation from
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.